Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World
Executive Summary
Payers might be open to keeping the Advair brand on formulary even if a generic becomes available, because GSK has a portfolio of respiratory drugs to leverage in negotiations, CEO Andrew Witty said during the company’s third quarter conference call.
You may also be interested in...
Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair
FDA approved Teva’s AirDuo RespiClick, which contains the active ingredients in GlaxoSmithKline’s Advair, but in the RespiClick device, which means it will not be an interchangeable generic.
Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair
FDA approved Teva’s AirDuo RespiClick, which contains the active ingredients in GlaxoSmithKline’s Advair, but in the RespiClick device, which means it will not be an interchangeable generic.
ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
Generics must be able to be administered without provider intervention or patient retraining, draft guidance says.